OPPORTUNITY
We are currently seeking a Sr. Scientist I, Neuromuscular Disorders - Gene Editing, who will be responsible for leading the research and early development activities for our preclinical gene editing projects in the rare neuromuscular disease space. In this role, the successful candidate and their team will be advancing optimized candidates from early development to in vivo models and towards clinical studies. In addition, the Sr. Scientist will be collaborating with Early Research, Screening and Assay Development, Gene Target Specificity, Viral Delivery, Non-Viral Delivery, mRNA Technologies, and in vivo Pharmacology teams as they lead the team to generate data on for efficacy, safety and mechanism of action of our novel therapeutic candidates.
KEY RESPONSIBILITIES
- Contribute to the research efforts on designing, testing, optimizing and selecting lead candidates for neuromuscular indications using our novel Mammoth Cas nuclease systems
- Lead from the bench junior and senior researchers to generate data to address neuromuscular disease, from proof-of-concept to development candidates
- Collaboratively lead and/or supervise the development of in vitro and in vivo functional assays to assess the delivery, safety and efficacy of our therapeutics
- Present data to management, cross-functional project teams, and external partners
- Propose and integrate methodologies, technologies, and hypotheses to advance the projects and deliver high-quality data
- Hire and mentor additions to the team
- Design and execute preclinical in vitro experiments to support optimization and drug product development, and employ relevant rodent or non-human primate models to characterize gene editing candidates
REQUIRED QUALIFICATIONS
- PhD in a life sciences discipline
- 4+ years of relevant research post-PhD experience in an industry or academic setting
- Experience with small molecule, gene therapy or nucleic acid therapy modalities for neuromuscular diseases
- Deep knowledge of genetic neuromuscular diseases and relevant in vitro and animal models of disease, including target disease validation
PREFERRED QUALIFICATIONS
- Familiarity with CRISPR technologies and gene therapy delivery systems (viral and non-viral)
- Experience with advanced primary in vitro cell culture of iPSCs, myoblast, myotubes and cardiomyocytes.
- Experience with iPSCs differentiation into myoblast, myotubes and cardiomyocytes.
- Experience with transfection methods of relevant cell types (Lipofection, nucleofection, AAV transduction).
- Immunostaining of in vitro cultured myoblast, myotubes and cardiomyocytes.
- Experience with primer design, cloning strategies, PCR, library preparation for next generation sequencing, RNA handling and cDNA library generation, qPCR and/or ddPCR.
- A strong foundation in experimental documentation, basic statistical analysis and data presentation
- Bioassay development and optimization
- Excellent oral and written communication skills
BENEFITS
- Company-paid health/vision/dental benefits
- Unlimited vacation and generous sick time
- Company-sponsored meals and snacks
- Wellness, caregiver and ergonomics benefits
- 401(k) with company matching
COMPANY
Mammoth Biosciences is harnessing the diversity of life to power the next generation of CRISPR products. Through the discovery and engineering of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth aims to develop permanent genetic cures through best-in-class in vivo and ex vivo therapies and to democratize disease detection with on-demand diagnostics. Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in the San Francisco Bay Area, Mammoth Biosciences is co-founded by CRISPR pioneer and Nobel Laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Redmile Group, Foresite Capital, Senator Investment Group, Sixth Street, Decheng, Mayfield, NFX, and 8VC, along with leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.
TEAM
Our small-size proteins, such as Cas14 and CasPhi, are poised to transform disease treatment enabling novel editing approaches and delivery options that are difficult to achieve or not even possible with previously described CRISPR-Cas systems. Our teams are responsible for discovering and engineering novel CRISPR systems, establishing CRISPR-based diagnostics, and translating our unique CRISPR technology into therapeutic treatments with the ultimate goal of cures for indications with high medical need.
It is our policy and intent to provide equal opportunity to all persons without regard to race, color, religion, political affiliation, sex/gender (including gender expression/identity, pregnancy, childbirth and related medical conditions), marital status, registered domestic partner status, sexual orientation, age, ancestry, national origin, veteran status, disability, medical condition, genetic characteristics, and/or any other basis protected by law. This policy covers all facets of employment including, but not limited to: recruitment, selection, placement, promotions, transfers, demotions, terminations, training, and compensation.
Mammoth Biosciences requires that all employees be vaccinated against COVID-19 as a condition of at-will employment, with exceptions for medical or religious reasons in compliance with local, state, and federal law.
